Page 97 - The Flying Publisher Guide to Hepatitis C Treatment

References | 97

Pearlman BL, Ehleben C, Saifee S, et al. Treatment extension to 72 weeks of
peginterferon and ribavirin in hepatitis C genotype 1-infected slow
responders. Hepatology 2007;46:1688-94.
Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV
genotype 1 infection. N Engl J Med 2011;364:1195-206.
Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in
patients infected with chronic hepatitis C virus genotypes 2 and 3. J
Hepatol 2008;48:28-34.
Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin:
effective in patients with hepatitis C who failed interferon alfa/ribavirin
therapy. Gastroenterology 2009;136:1618–28.
Poynard T, Schiff E, Terg R, et al. Sustained viral response is dependent on
baseline characteristics in the retreatment of previous alfa
interferon/ribavirin nonresponders: final results from the EPIC3 program.
J Hepatol 2008;48:S369.
Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic
findings in chronic hepatitis C: a European collaborative study. Hepatology
2002;36:973-7.
Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated
with chronic hepatitis C and treatment failure: A genome-wide association
study. Gastroenterology 2010;138:1338-45.
Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in
hepatitis C virus genotype 1 patients completing peginterferon alfa-
2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-9.
Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L. Monitoring
hepatitis C virus infection among injecting drug users in the European
Union: a review of the literature. Epidemiol Infect 2002;129:577-85.
Saab S, Oh M, Ibrahim A, et al. Anemia in liver transplant recipients undergoing
antiviral treatment for recurrent hepatitis C. Liver Transpl 2007;13:1032-8.
Samonakis DN, Triantos C, Thalheimer U, et al. Immunosuppresion and donor age
with respect to severity of HCV recurrence after liver transplantation.
Liver Transpl 2005;11:386-95.
Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon alfa2a plus ribavirin
for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at
week 4 of treatment. Gastroenterology 2006;131:451-60.
Sarrazin C, Shiffman ML, Hadziyannis SJ, et al. Definition of rapid virologic
response with a highly sensitive real-time PCR-based HCV RNA assay in
peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol
2010;52:832-8.
Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection. A
systematic review. JAMA 2007;297:724-32.
Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential
for interaction with antiretrovirals. J Antimicrob Chemother 2010;65:1079-
85.
Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications
of the graft in interferon-treated hepatitis C positive liver transplant
recipients. J Hepatol 2011;55:207-17.